Stay updated with breaking news from Cornea Fellowship Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MENLO PARK, Calif., Dec. 18, 2023 -- Sight Sciences, Inc. , an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve...
Learn about demodex blepharitis, a common eye disorder caused by microscopic mites. Discover the FDA-approved treatment Xdemvy, its effectiveness, safety, and availability.
XDEMVY is the first and only approved therapeutic for Demodex blepharitis, a highly prevalent eyelid disease that impacts approximately 25 million eye care patients in the U.S. XDEMVY targets the...
MENLO PARK, Calif., July 20, 2023 -- Sight Sciences, Inc. , an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve...
13.09.2022 - 310-patient RCT designed to evaluate the superiority of TearCare (device) vs Restasis (drug) in patients with chronic dry eye disease is now fully enrolled6-Month efficacy results expected by Summer 2023 MENLO PARK, Calif., Sept. 13, 2022 ... Seite 1